生物制剂治疗川崎病的进展

摘要/Abstract

摘要：

川崎病（KD）是一种由全身血管炎症病变引发的儿童急性发热出疹性疾病，近年来发病率呈现出增加的趋势。传统治疗方法部分患儿效果不佳，且并发症发生率较高。因此选择合适的KD治疗方案，是当前迫切需要解决的问题。随着生物医学及药物学地不断发展，各种生物制剂应运而生，临床上逐渐用新型生物制剂代替传统的治疗方法，已取得了较为理想的效果。文章综述几种常见的生物制剂在KD临床治疗中的应用进展，旨在为KD有效治疗提供新的参考。

Abstract: Kawasaki disease (KD) is a systemic vascular inflammatory lesion in children with acute febrile rash illness. The incidence rate in recent years is increasing. The traditional treatment in some patients is ineffective, and KD has high incidence of cardiovascular complications. Therefore, the selection of an appropriate therapy for KD is an urgent. With the continuous advance of biomedical and pharmacologically research, many biological agents were developed. The traditional treatment has been gradually replaced by the new biological agents which achieved the desired results. Thus this paper reviewed several common biological agents in the clinical treatment of KD.

李卓颖，杨作成. 生物制剂治疗川崎病的进展[J]. 临床儿科杂志, 2014, 32(6): 595-598.

　LI Zhuoying,YANG Zuocheng. Progress in biological agents for treatment of Kawasaki disease[J]. , 2014, 32(6): 595-598.

参考文献

[1] 黄麟，杨作成. 川崎病发病机制的研究进展 [J]. 中华儿科杂志，2009，47(4): 265-267.
[2] Natividad MF，Torres-Villanueva CA，Saloma CP. Superantigen involvement and susceptibility factors in Kawasaki disease: profiles of TCR Vβ2+ T cells and HLA-DRB1，TNF-α and ITPKC genes among Filipino patients [J]. Int J Mol Epidemiol Genet，2013，4(1):70-76.
[3] Takahashi K，Oharaseki T，Yokouchi Y. Pathogenesis of Kawasaki disease [J]. Clin Exp Immunol，2011，164(Suppl 1): 20-22.
[4] 罗建平，龚方威. 川崎病并发冠状动脉研究进展 [J]. 国际儿科学杂志，2012，39(2): 135-137.
[5] Lee EJ，Park YW，Hong YM，et al. Epidemiology of Kawasaki disease in infants 3 months of age and younger [J]. Korean J Pediatr，2012，55(6): 202-205.
[6] Lee G，Lee SE，Hong YM，et al. Is high-dose aspirin necessary in the acute phase of Kawasaki disease? [J]. Korean Circ J，2013，43(3): 182-186.
[7] Burns JC，Herzog L，Fabri O，et al. Seasonality of Kawasaki disease: a global perspective [J]. PLoS One，2013，8(9): e74529.
[8] Inciarte-Mundo J，Hernández MV，Rosario V，et al. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions [J]. Reumatol Clin，2014，10(1): 10-16.
[9] Lima HC，Kimball AB. Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis [J]. Indian J Dermatol，2010，55(2): 171-175.
[10] 周炯，郑敏. 新型生物制剂在关节病型银屑病中的应用 [J]. 浙江大学学报: 医学版，2009，38(4): 404-408.
[11] Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept，infli-ximab and adalimumab [J] . J Dermatolog Treat，2004，15( 5) : 280-294.
[12] Imrie FR，Dick AD. Biologics in the treatment of uveitis [J]. Curr Opin Ophthamlol，2007，18 ( 6): 481-486.
[13] Kuo HC，Yu HR，Wu CC，et al. Etanercept treatment for children with refractory juvenile idiopathic arthritis [J]. J Microbiol Immunol Infect，2011，44(1): 52-56.
[14] Muta H，Ishii M，Egami K，et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan [J]. J Pediatr，2004，144(4) : 496-499．
[15] Fukuda S，Ito S，Oana S，et al. Late development of coronary artery abnormalities could be associated with persistence of non-fever symptoms in Kawasaki disease [J]. Pediatr Rheumatol Online J，2013，11(1):28.
[16] Yeo JS，Choi JW. Effectiveness of medium-dose intravenous immunoglobulin (1 g /kg) in the treatment of Kawasaki disease [J]. Korean Circ J，2010，40(2): 81-85.
[17] Inoue Y，Okada Y，Shinohara M，et al．A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome [J]. J Pediatr，2006，149(3): 336-341.
[18] Song MS，Lee SB，Sohn S，et al. Infliximab treatment for refractory Kawasaki disease in Korean children [J]. Korean Circ J，2010，40(7): 334-338.
[19] Newburger JW，Sleeper LA，McCrindle BW，et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease [J]. N Engl J Med，2007，356(7): 663-675.
[20] Son MB，Gauvreau K，Burns JC，et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study [J]. J Pediatr，2011，158(4): 644-649.
[21] Choueiter NF，Olson AK，Shen DD，et al. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease [J]. J Pediatr，2010，157(6): 960-966.
[22] Portman MA，Olson A，Soriano B，et al. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale [J]. Am Heart J，2011，161(3): 494-499.
[23] Ohashi R，Fukazawa R，Watanabe M，et al. Etanercept suppresses arteritis in a murine model of Kawasaki disease: a comparative study involving different biological agents [J]. Int J Vasc Med，2013，2013: 543141.
[24] Mertens M，Singh JA. Anakinra for rheumatoid arthritis: a systematic review [J]. J Rheumatol，2009，36(6): 1118-1125.
[25] Abbate A，Salloum FN，Vecile E，et al. Anakinra，a recombinant human interleukin-1 receptor antagonist，inhibits apoptosis in experimental acute myocardial infarction [J]. Circulation，2008，117(20): 2670-2683.
[26] Lee Y，Schulte DJ，Shimada K，et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease [J]. Circulation，2012，125(12): 1542-1550.
[27] Pescovitz MD，Greenbaum CJ，Krause-Steinrauf H，et al. Rituximab，B- lymphocyte depletion，and preservation of beta-cell function [J]. N Engl J Med，2009，361(22): 2143-2152.
[28] Eleftheriou D，Melo M，Marks SD，et al. Biologic therapy in primary systemic vasculitis of the young [J]. Rheumatology (Oxford)，2009，48(8): 978-986.
[29] Benucci M，Saviola G，Manfredi M，et al. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis [J]. Biologics，2013，7: 69-75.
[30] Sauvaget E，Bonello B，David M，et al. Resistant Kawasaki disease treated with anti-CD20 [J]. J Pediatr，2012，160(5): 875-876 .
[31] Athappan G，Gale S，Ponniah T. Corticosteroid therapy for primary treatment of Kawasaki disease-weight of evidence: a meta-analysis and systematic review of the literature [J]. Cardiovasc J Afr，2009，20(4): 233-236.
[32] Chen YT，Liao WL，Lin YJ，et al. Association between SRC-1 gene polymorphisms and coronary artery aneurysms formation in Taiwa-nese children with Kawasaki disease [J]. J Clin Lab Anal，2014，Mar 20.doi：10.1002/jcla.21706.
[33] Tembhare PR，Marti G，Wiestner A，et al. Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia [J]. Am J Clin Pathol，2013，140(6): 813-818.
[34] Johnson PN，Kuhn RJ. Combination thrombolytic and anti-platelet therapies in an infant with incomplete Kawasaki disease and coronary aneurysms [J]. J Pediatr Pharmacol Ther，2008，13(4): 242-250.
[35] Gedalia A. Kawasaki disease: 40 years after the original report [J]. Curr Rheumatol Rep，2007，9(4): 336-341．
[36] Gavin PJ，Crawford SE，Shulman ST，et al. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease [J]. Arterioscler Thromb Vasc Biol，2003，23(4): 576-581.